Renin–Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome by Hrenak, Jaroslav & Simko, Fedor
 
Int. J. Mol. Sci. 2020, 21, 8038; doi:10.3390/ijms21218038 www.mdpi.com/journal/ijms 
Review 
Renin–Angiotensin System: An Important Player  
in the Pathogenesis of Acute Respiratory  
Distress Syndrome 
Jaroslav Hrenak 1,2,† and Fedor Simko 2,3,4,*,† 
1 Department of Cardiovascular Surgery, Inselspital – University Hospital of Bern, Freiburgstrasse 18,  
3010 Bern, Switzerland; jaroslav.hrenak@insel.ch 
2 Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4,  
811 08 Bratislava, Slovakia 
3 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, Limbova 5,  
833 05 Bratislava, Slovakia 
4 Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 
Dúbravská cesta 9, 845 05 Bratislava, Slovakia 
* Correspondence: fedor.simko@fmed.uniba.sk 
† These authors equally contributed to this work. 
Received: 5 October 2020; Accepted: 26 October 2020; Published: 28 October 2020 
Abstract: Acute respiratory distress syndrome (ARDS) is characterized by massive inflammation, 
increased vascular permeability and pulmonary edema. Mortality due to ARDS remains very high 
and even in the case of survival, acute lung injury can lead to pulmonary fibrosis. The 
renin–angiotensin system (RAS) plays a significant role in these processes. The activities of RAS 
molecules are subject to dynamic changes in response to an injury. Initially, increased levels of 
angiotensin (Ang) II and des-Arg9-bradykinin (DABK), are necessary for an effective defense. Later, 
augmented angiotensin converting enzyme (ACE) 2 activity supposedly helps to attenuate 
inflammation. Appropriate ACE2 activity might be decisive in preventing immune-induced 
damage and ensuring tissue repair. ACE2 has been identified as a common target for different 
pathogens. Some Coronaviruses, including SARS-CoV-2, also use ACE2 to infiltrate the cells. A 
number of questions remain unresolved. The importance of ACE2 shedding, associated with the 
release of soluble ACE2 and ADAM17-mediated activation of tumor necrosis factor-α 
(TNF-α)-signaling is unclear. The roles of other non-classical RAS-associated molecules, e.g., 
alamandine, Ang A or Ang 1–9, also deserve attention. In addition, the impact of established 
RAS-inhibiting drugs on the pulmonary RAS is to be elucidated. The unfavorable prognosis of 
ARDS and the lack of effective treatment urge the search for novel therapeutic strategies. In the 
context of the ongoing SARS-CoV-2 pandemic and considering the involvement of humoral 
disbalance in the pathogenesis of ARDS, targeting the renin–angiotensin system and reducing the 
pathogen’s cell entry could be a promising therapeutic strategy in the struggle against COVID-19. 
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1. Introduction 
Acute respiratory distress syndrome (ARDS) is defined as an acute, diffuse, inflammatory lung 
injury, leading to increased pulmonary vascular permeability, increased lung weight, and loss of 
aerated lung tissue [1]. An efficient pharmacological treatment is lacking and mechanical lung 
ventilation or even extracorporeal membrane oxygenation is needed to ensure sufficient gas 
exchange. Despite great progress in this field, overall mortality is 45% [2]. Moreover, mechanical s
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ventilation itself can contribute to lung injury. The prevalence of ventilator-associated lung injury is 
6.2% among mechanically ventilated patients [3,4]. The most common risk factor for developing 
ARDS is pneumonia (35–50%), followed by non-pulmonary sepsis (30%), aspiration (10%), and 
trauma (10%) [5]. The pathogenesis of ARDS involves diffuse alveolar damage, inflammation with a 
cytokine storm and increased capillary permeability, resulting in the development of pulmonary 
edema, decreased lung compliance and impaired gas exchange [6]. The reabsorption of alveolar and 
interstitial fluid is associated with the proliferation of type II alveolar cells as well as fibroblasts and 
myofibroblasts producing components of the extracellular matrix. These processes can lead either to 
the restoration of normal pulmonary tissue or to fibrotic remodeling of the lungs [7]. The underlying 
mechanisms determining the loss of lung parenchyma and fibrosis development are still 
insufficiently understood. 
The renin–angiotensin system (RAS) (Figure 1) represents one of the most important regulatory 
mechanisms in both physiological and pathological conditions [8,9]. Its components are present in 
various tissues and are involved in a number of biological pathways [8,10,11]. The RAS has been 
known for over 120 years and has been mostly studied in relation to blood pressure regulation and 
cardiovascular disorders [12–15]. In addition to their hemodynamic effects, components of the RAS 
act in various organs and systems as signaling molecules modulating inflammation, oxidative stress, 
cell proliferation, tissue remodeling, and apoptotic or necrotic cell death [15–19]. 
In the last three decades, several other “non-classical” RAS peptides such as the type 2 
angiotensin II receptor (AT2R) [20,21], the angiotensin converting enzyme (ACE) 2 [22], angiotensin 
(Ang) 1–7 [23], alamandine and Ang A [11] or Ang 1–9 [24] have been identified. Recent data suggest 
that they are more than inactive splitting products. They are involved in various reactions at the 
cellular and organ levels [8,9]. Nowadays, the concept of two counterbalancing axes is generally 
accepted. The classical cascade, represented by ACE/Ang II/AT1R, exerts vasoconstrictor, 
pro-inflammatory and profibrotic effects. The other, involving ACE2, Ang 1–7 and the Mas receptor 
(MasR), mediates the vasodilatory, anti-inflammatory and anti-fibrotic actions of the RAS. However, 
the interactions of the RAS family members are multidirectional, involving a bulk of molecules 
whose physiological role has yet to be elucidated [8,11,25]. In addition, the RAS is closely related to 
the kinin–kalikrein system, regulating vascular tone and permeability, since ACE and ACE2 
participate in the inactivation of bradykinin and des-Arg9-bradykinin (DABK), respectively [26,27]. 
 
Figure 1. Renin–angiotensin system. ACE—angiotensin-converting enzyme; 
ACE2—angiotensin-converting enzyme 2. Ac-SDKP—N-acetyl-seryl-aspartyl-lysyl-proline; 
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DABK—des-Arg9-bradykinin; CxA—carboxypeptidase A; CATA—cathepsin A; NEP—neprilysin; 
POP—propyl oligopeptidase; APA—aminopeptidase A; MLDAD—mononuclear leukocyte-derived 
aspartate decarboxylase; APM—aminopeptidase M, AT1, AT2, AT3 angiotensin receptor type 1, 2, 3, 
respectively; MrgD— Mas-Related G-Protein Coupled Receptor D; Mas—Mas receptor. 
2. RAS and Pulmonary Diseases 
An upregulation of Ang II/AT1R-mediated signaling has been identified in various pathologic 
conditions, including pulmonary diseases [18,28]. Indeed, the activation of the ACE/Ang II/AT1R 
cascade is associated with increased pneumonia risk and worse prognosis [29]. In experimental 
lipopolysaccharide (LPS)-induced lung fibrosis, Ang II levels were slightly elevated in the plasma 
and even more increased in the bronchoalveolar lavage fluid. These changes were accompanied by 
higher AT1R expression in the pulmonary tissue [30]. Similarly, increased Ang II levels were also 
detected in the serum of patients with avian influenza H5N1 [31]. ARDS non-survivors were 
reported to have had significantly higher Ang I levels [32]. Patients with influenza (H7N9) 
discharged from hospital within 28 days presented a decline in Ang II plasma levels after the first 
week, whereas they remained elevated in patients who required longer hospitalization and in 
non-survivors [33]. 
On the other hand, stimulation of the Ang 1–7/ACE2 axis seems to be beneficial in acute lung 
injury. Treatment with human recombinant ACE2 attenuated bleomycin-induced fibrosis and 
improved pulmonary function in ACE2 wild-type mice [34]. Intravenous administration of ACE2 
also attenuated the LPS-induced overexpression of pro-inflammatory cytokines interleukin (IL)-1β, 
IL-6 and tumor necrosis factor α (TNF-α) [35]. In mice infected with H5N1 influenza virus, treatment 
with recombinant ACE2 reduced the virus replication in the lungs and even reduced mortality [31]. 
Similarly, the administration of Ang 1–7 in rats subjected to acid aspiration and high stretch 
ventilation reduced the number of inflammatory cells in bronchoalveolar lavage and attenuated 
pulmonary fibrosis two weeks after the acid aspiration injury [36]. The beneficial effects of Ang 1–7 
administration in LPS-induced lung injury were related to a downregulation of AT1R [30]. 
3. Regulatory, Rather than Harmful or Protective 
Generally, the two principal RAS pathways—ACE/Ang II/AT1R and ACE2/Ang 
1–7/MasR—are designated as deleterious and protective, respectively. However, these two cohorts 
of apparently counterregulatory molecules are more likely to be involved in complex and 
sophisticated regulatory processes and their positive or negative impact depends on a wide variety 
of factors. 
An overwhelming activity of the pro-inflammatory Ang II-mediated cascade in relation to the 
ACE2/Ang 1–7 pathway seems to be necessary for an adequate immune response to respiratory 
infections. Lower ACE2 levels stimulate neutrophil accumulation in the lungs, which is an important 
step in defending against microbial invasion [37,38]. Besides Ang II and Ang A, ACE2 cleaves 
another pro-inflammatory mediator, DABK, in the respiratory system [27]. Attenuated ACE2 
activity in response to bacterial infection leads to decreased inactivation and increased 
bioavailability of DABK, resulting in the release of pro-inflammatory mediators such as C-X-C motif 
chemokine 5 (CXCL5), macrophage inflammatory protein-2 (MIP2), C-X-C motif chemokine 1 (KC), 
and tumor necrosis factor (TNF)-α from airway epithelia, and increased neutrophil infiltration [27]. 
Thus, in the early stages of a bacterial infection, the dynamic balance within the RAS is prone to be 
shifted towards Ang II and DABK to recruit immunocompetent cells to the lungs. Later, ACE2 
activity increases to avoid excessive inflammation and cytokine-related tissue damage. The existence 
of both axes within the RAS seems to be unavoidable for the proper regulation of the immune 
response, which requires dynamic changes in the activities of the RAS-associated compounds in the 
course of the inflammatory reaction. ACE/Ang II/AT1R signaling thus becomes deleterious in the 
case of disrupted equilibrium within the RAS (Figure 2). 
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Figure 2. Putative role of the renin–angiotensin system in the progression of acute lung injury. 
ACE2—angiotensin-converting enzyme 2; Ang II—angiotensin II; Ang A—angiotensin A; 
DABK—des-Arg9-bradykinin; Ang 1–7—angiotensin 1–7. 
4. ACE2: Conductor of Inflammatory Response in the Lungs 
ACE2, a carboxypeptidase identified in 2000 as a human homologue of ACE, is apparently a 
key molecule regulating inflammation in the respiratory system (Figure 3). ACE2 exhibits 
approximately 40% identity and 61% similarity compared to ACE [22]. Due to the slight structural 
difference between ACE and ACE2, ACE inhibitors do not inhibit ACE2 activity [39]. Several natural 
substrates for ACE2 have been identified. The best-studied pathway is the conversion of Ang II to 
generate Ang 1–7 [23]. ACE2 also further metabolizes Ang A to alamandine [11] as well as other 
peptides, including DABK, apelin, neurotensin, dynorphin, ghrelin [8,22,27,40,41–43]. The formation 
of Ang 1–9 from Ang I has also been reported; however, its role in vivo is disputable since the kinetic 
of the reaction is rather poor [39,42]. 
High ACE2 gene expression has been found in the heart, kidney, brain, lungs, oral mucosa, 
liver and small intestine [22,43–47]. A recent analysis of human tissues showed that ACE2 was 
predominantly expressed on the barrier sides of bronchial or skin cells and was more abundant in 
the bronchial biopsies of smokers [48]. ACE2 occurs in membrane-bound (mACE2) and soluble 
(sACE2) forms. The ectodomain of mACE2 is cleaved from the cell membrane and subsequently 
released as sACE2 into the interstitial space and circulation [49,50]. This splitting happens in a 
constitutive or inducible way [49,51,52], by the enzymatic action of the tumor necrosis factor-α 
(TNF-α)-converting enzyme (TACE), also known as ADAM17 [50], or other sheddases [51]. 
Importantly, sACE2 was shown to maintain its catalytic activity [49]. 
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ADAM17-dependent ACE2 shedding can be induced by Ang II via AT1R as well as by elevated 
glucose levels or by several members of the Coronavirus family, including SARS-CoV and 
SARS-CoV-2 [52–57]. Higher sACE2 plasma levels were observed in men compared to women, the 
older population, post-menopausal women and in patients with metabolic syndrome or heart failure 
[58–60]. The role of ACE2 shedding under physiological and pathological conditions remains, 
however, insufficiently understood. Non-sheddable ACE2 exerted impaired enzymatic activity, 
indicating that attenuated ACE2 shedding might be involved in the pathogenesis of several diseases 
[18]. On the other hand, enhanced ACE2 shedding in the brain was shown to contribute to the 
pathogenesis of deoxycorticosterone acetate (DOCA)-salt-induced hypertension in mice [61]. 
ADAM17 catalyzes, among others, the activation of pro-TNF-α to TNF-α [50]. Increased 
ADAM17 activity was detected in several pathologies, such as diabetes mellitus, hypertension, 
inflammatory processes, cardiovascular disorders, neurological and oncological diseases [50,61]. A 
knockdown of ADAM17 in the DOCA-salt hypertensive model prevented the decline in ACE2 in the 
brain and attenuated hypertension, whereas an overexpression of ACE2 was associated with 
reduced ADAM17 levels [61]. 
Importantly, the ADAM17-mediated pathway is not the only mechanism to cleave ACE2 from 
the cell surface [18,51]. The inhibition of ADAM17 in proximal tubular cells in mice did not abolish 
the constitutive ACE2 shedding [52,53] but it was inhibited by blocking protein kinase C-δ (PKC-δ) 
[53]. In addition, under experimental conditions, at least two forms of sACE2, referred to as the large 
and small soluble forms, differing in their molecular masses, have been identified, while ADAM17 is 
only involved in the generation of the large soluble form of ACE2 [51]. 
 
Figure 3. Regulatory role of angiotensin-converting enzyme 2 in the pathogenesis of acute lung 
injury and ARDS. Increasing/decreasing activity of the angiotensin-converting enzyme 2 (ACE2) 
regulates the dynamic balance within the RAS. Ang II—angiotensin II; Ang A—angiotensin A; 
DABK—des-Arg9-bradykinin; Ang 1–7—angiotensin 1–7; Ang 1–9—angiotensin 1–9. 
5. Interactions with Infectious Agents 
Considering the fact that infectious diseases, particularly pneumonia and sepsis, account for the 
greatest number of ARDS cases [5], understanding the mutual interactions between the RAS and 
microbial agents is of significant value. 
Attenuated ACE2 activity was observed in LPS-induced pneumonia, which represents a 
well-established experimental model of bacterial respiratory infection. Although LPS enhanced 
ACE2 gene expression, transcriptional and posttranscriptional modifications led to its reduced 
bioavailability in mouse lungs [27]. The influenza virus also downregulates ACE2, most likely due to 
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the direct catalytic action of virus surface protein neuraminidase, followed by further protein 
degradation by the proteasome pathway [62]. ACE2 degradation has no impact on the replication of 
the influenza virus [62,63]; however, it is conceivable that lower ACE2 bioavailability can affect the 
immune response to the infection and facilitate the progression of the disease. 
The SARS epidemic in 2003 as well the current COVID-19 pandemic, caused by two members of 
the Coronavirus family SARS-CoV and SARS-CoV-2, respectively, have directed attention towards 
the interaction of Coronaviruses with the RAS. mACE2 serves as a binding site for SARS-CoV [64,65] 
and SARS-CoV-2 [66,67], mediating the entry of the virus into the host cell. A mutation in the 
receptor-binding domain of the SARS-CoV-2 spike protein S compared to SARS-CoV is responsible 
for a higher affinity of SARS-CoV-2 to ACE2 [67]. 
mACE2, among others, is highly expressed by type II alveolar cells, facilitating virus entry and 
replication in these cells [68]. The internalization of the virus into the host cells requires a priming of 
the spike protein S after binding to mACE2, which is associated with cleavage at the S1/S2 and the S2 
sites by transmembrane protease serine 2 (TMPRSS2) [69]. ACE2 and TMPRSS2 co-expression on 
type II alveolar cells or nasal epithelial cells facilitates the infection of the host cells [69,70]. 
Interaction with the SARS-CoV spike protein induces the downregulation of ACE2 [65,71], 
preventing co-infection by other intracellular pathogens [56,71]. The binding of the SARS-CoV spike 
protein to ACE2 led to attenuated ACE2 protein expression in vivo as well as to a reduced number of 
mACE2 in Vero E6 cells [65]. Another mechanism contributing to the loss of mACE2 is the 
ADAM17-dependent shedding of ACE2 [56]. Importantly, only mACE2 can mediate virus entry into 
the cell [49]. However, released sACE2 retains the ability to bind the virus and inhibit its 
internalization into the cells [49,72]. 
Another human Coronavirus (HCoV)-NL63, causing the common cold, also attenuates ACE2 
expression in infected cells, while this effect is proportional to virus replication efficacy [73]. 
However, the spike protein of HCoV-NL63 has lower affinity to ACE2 compared to SARS-CoV, 
which determines its lower virulence [71]. 
The ways in which different microorganisms interfere with the RAS are probably 
agent-specific, while ACE2 downregulation seems to be the common feature. Attenuated ACE2 
activity presumably facilitates prolonged and more intense activation of the pro-inflammatory 
RAS-associated pathways, leading to immune-induced tissue damage and fibrosis development in 
the later course of the disease. 
6. Pharmacological Inhibition of ACE and AT1R in Pulmonary Diseases 
ACE inhibitors (ACEIs) or AT1R blockers (ARBs) are well established in the treatment of 
hypertension, heart failure, renal pathologies and the prevention of atherosclerotic complications. 
Considering the role of the RAS in the pathogenesis of pulmonary diseases, pharmacological 
antagonists of the RAS could modulate the evolution of lung injury by interfering with local RAS in 
the lungs (Table 1). 
An in vitro assay on LPS-treated isolated cells showed that the administration of the ACEI 
enalapril, ARB valsartan or both alleviated LPS-induced pulmonary inflammation [35]. In clinical 
settings, a number of data indicate the potential benefit of ACEIs/ARBs in pulmonary inflammatory 
diseases. A large population-based cohort study involving more than 250,000 Canadian patients 65 
years of age or older documented a reduced number of hospitalizations with pneumonia in the first 
90 days after the initiation of antihypertensive therapy in favor of ACEIs or ARBs compared to other 
antihypertensive drugs [74]. A smaller Korean study showed reduced pneumonia risk in elderly 
patients (aged <70 years) with chronic obstructive pulmonary disease (COPD) treated with ACEIs or 
ARBs [75]. A retrospective analysis of 215,225 American patients revealed that treatment with ACEIs 
or ARBs slowed the progression of pulmonary complications in COPD patients [76]. The analysis of 
the medical records of 182 ARDS patients showed an increased survival rate in patients treated with 
ACEIs or ARBs [77]. The Cox regression analysis of the data obtained in the longitudinal 
observational Fremantle Diabetes Study Phase II, found that the use of ACEIs/ARBs was associated 
with a reduced risk of pneumonia/influenza in patients with type 2 diabetes mellitus [78]. 
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Table 1. Effect of pharmacological inhibition of the renin–angiotensin system on respiratory 
pathologies. ACEIs—angiotensin-converting enzyme inhibitors; ARBs—angiotensin II-receptor type 
1 (AT1R) blockers; COPD—chronic obstructive pulmonary disease; ICU—intensive care unit; 
T2D—type 2 diabetes mellitus. 
Study Design Subjects Outcome Ref. 
Retrospective 
cohort study 
254,485 patients > 65 y.o. 
newly prescribed 
antihypertensive drugs 
↓ risk of hospitalization with pneumonia 
within 90 days following treatment initiation 
with ACEIs/ARBs vs. other antihypertensive 
drugs 
[74] 
Retrospective 
nested 
case–control study 
375 COPD patients  ↓ risk of pneumonia [75] 
Retrospective 
comparative study 
12,452 patients newly 
prescribed ACEIs/ARBs within 
90 days after diagnosis of 
COPD 
↓ risk of pneumonia, severe pneumonia and  
↓ mortality in ARBs group vs. ACEIs 
[76 
Retrospective 
cohort study 
215,225 patients  
Improved infectious (influenza, pneumonia), 
inflammatory (COPD) and structural 
outcomes in ACEIs/ARBs vs. other treatment 
[77] 
Retrospective 
case–control study 
182 ARDS patients 
↑ duration of mechanical ventilation and ICU 
stay in ACEIs/ARBs group  
↑ survival in ACEIs/ARBs group 
[78] 
Cox regression  
longitudinal 
observational 
study 
1482 T2D patients ↓ risk of pneumonia/influenza [79] 
7. ACEIs and ARBs in COVID-19 
The global COVID-19 pandemic has raised concerns regarding the impact of ACEIs and ARBs 
on susceptibility to SARS-CoV-2 and the severity of the infection. Since the virus uses mACE2 to 
enter into the host cells, some authors have hypothesized that increased ACE2 bioavailability related 
to treatment with ACEIs or ARBs might facilitate the entry of SARS-CoV-2 into the cells [80,81]. 
However, the current evidence does not support this opinion [82]. A meta-analysis of nine studies 
including 3936 patients with hypertension and COVID-19 demonstrated that treatment with ACEIs 
and/or ARBs had no impact on the severity of the disease; moreover, it was associated with 
decreased mortality [83]. Another meta-analysis based on eighteen studies involving a total of 17,311 
subjects demonstrated a 16% risk reduction in the composite outcome (death, admission to intensive 
care unit, mechanical ventilation requirement or progression to severe or critical pneumonia) in 
SARS-CoV-2-infected hypertensive patients treated with ACEIs or ARBs compared to no treatment 
or treatment with other substances than ACEIs/ARBs [84]. The most recent meta-analysis of 25 
observational studies demonstrated a neutral effect of ACEI/ARB treatment on SARS-CoV-2 
infection, disease severity, hospital/intensive care unit (ICU) admission or SARS-CoV-2-related 
death; however, the subgroup analysis revealed a decreased risk of critical illness and death in Asian 
populations, and an increased risk for ICU admission or death in North America and Europe, 
respectively [85]. 
Several theories aiming to explain the effect of RAS inhibiting treatment on SARS-CoV-2 
infection at cellular and/or subcellular levels have been proposed [25,86,87]. However, the 
physiological and pathological roles of the majority of the involved molecules remain only partly 
understood and the complexity of their interactions raises a number of questions requiring further 
investigation. 
Firstly, the impact of ACEIs and ARBs on ACE2 levels and activity has yet to be fully 
elucidated, since the available data are discrepant. For example, treatment with lisinopril in an 
animal experiment did not affect renal ACE2 activity [88]. AT1R blockade was associated with 
enhanced cardiac ACE2 expression and activity, whereas the co-administration of lisinopril and 
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losartan led only to an increase in ACE2 activity but not to an elevation of mRNA expression [89]. 
Enalapril prevented a decline in ACE2 expression and activity after experimental myocardial 
infarction [90]; however, in a similar model, ramipril alone or in combination with valsartan failed to 
increase cardiac ACE2 [91]. In tissue samples from gastrointestinal endoscopy, ACE2 mRNA was 
increased in patients treated with ACE inhibitors but not with ARBs [92]. A Japanese cohort study 
involving 617 patients detected elevated urinary levels of ACE2 exclusively in patients treated with 
olmesartan, but not with other ARBs or ACEIs [93]. In a recent study, treatment with ACEIs or ARBs 
failed to increase plasma levels of ACE2 in two independent cohorts of heart failure patients [60]. 
These unequivocal and confusing findings indicate that the effect of antihypertensive treatment 
on ACE2 may vary depending on the drug and/or clinical conditions. ACEIs and ARBs have distinct 
mechanisms of actions and influence the components of the RAS in different ways. Treatment with 
ACEIs is associated with an accumulation of Ang I, Ang 1–7 and bradykinin, whereas ARBs do not 
influence the activity of bradykinin [26,94]. The effects on the systemic and local RAS are also 
diverse. For example, treatment with ARBs is related to strongly elevated plasma levels of Ang II 
[94]; however, renal or brain Ang II activities were shown to be attenuated during the administration 
of ARBs [95,96]. 
Similarly, there is a lack of information about the effect of antihypertensive agents on soluble 
and membrane-anchored ACE2. It is not obvious if ever or to what extent treatment with RAS 
inhibiting drugs affects ACE2 gene expression or the release of sACE2 from the cell membrane. 
Increased levels of Ang II in the case of treatment with ARBs might stimulate ACE2 shedding. On 
one hand, sACE2 is still able to catalyze the conversion of Ang II to Ang 1–7 as well as to bind 
coronaviruses, thus blocking their internalization by the target cells [49]. On the other hand, Ang 
II-induced shedding of ACE2 is associated with the activation of the ADAM17-mediated pathway 
[52,54], resulting in enhanced intracellular TNF-α-signaling, which contributes to tissue damage 
[56,57,97]. These unresolved questions, resulting in contradictory hypotheses, indicate that the 
modulation of the RAS by ACEIs and ARBs is complex and tissue specific. The clinical impact of 
ACEIs and ARBs may be settled by the ongoing prospective clinical trials [98]. 
8. Other Non-Classical RAS Components 
Although ACE2 seems to be the key regulator in acute lung injury and ARDS, other 
non-classical RAS-associated molecules, such as alamandine, Ang 1–9, 
N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) and the related alternative metabolic pathways also 
deserve attention. Since these molecules were shown to modulate inflammatory response in several 
organs, their potential interference with immune processes in the lungs should be considered. 
Alamandine, a heptapeptide differing from Ang 1–7 in only one amino acid residue, is 
generated from Ang II metabolite Ang A or directly from Ang 1–7 by the catalytic action of ACE2 
[11]. Alamandine attenuated neutrophil degranulation and induced the anti-inflammatory 
reprogramming of macrophages under inflammatory conditions in vitro as well as in vivo in mice 
[99,100] and improved cardiac function in LPS-induced sepsis by attenuating inflammatory reaction 
[101]. Oral administration of alamandine was associated with reduced expression of 
pro-inflammatory genes CCL2, TNF-α and IL-1β in the aorta in the mice model of transverse aortic 
constriction [102]. Presumably, the downregulation of ACE2 in acute lung injury may abrogate the 
cleavage of Ang A, which instead of being converted to the anti-inflammatory compound 
alamandine, can react directly with AT1R, contributing to pro-inflammatory and pro-fibrotic effects. 
It is thus reasonable to suppose that the potential protective effect of ACE2 in respiratory 
pathologies could in part be mediated by enhanced conversion of Ang A to alamandine. 
Ang 1–9, another active metabolite generated in an alternative pathway from Ang I, can be 
further converted to Ang 1–7 or act directly on the AT2R [103]. Based on current knowledge, the 
molecule is considered as anti-inflammatory and anti-fibrotic. The administration of Ang 1–9 led to 
decreased ACE activity and reduced Ang II formation in the hearts of diabetic rats [104]. In the rat 
DOCA-salt model of hypertension, Ang 1–9 attenuated inflammation and protected against organ 
fibrosis in the heart, aorta and kidney [105]. In experimental pulmonary hypertension in rats, Ang 
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1–9 reduced plasma levels of inflammatory cytokines, such as TNF-α, MCP-1, IL-1β and IL-6, and 
reversed changes in the expression of apoptosis-related proteins, such as Bax, Bcl-2, Caspase-3 and 
-9 in the lungs [106]. 
Ac-SDKP, an alternative substrate for ACE, has been investigated in several pathologies 
regarding its antifibrotic, antiproliferative and anti-inflammatory properties [10]. Ac-SDKP was 
shown to reverse inflammation and fibrosis in the heart [107,108], aorta [109], kidney [110], liver 
[111] and lungs [112,113]. In in vitro assays, Ac-SDKP suppressed silicon dioxide-induced apoptosis 
in human alveolar type II epithelial cells (A549) [114]. Similarly, Ac-SDKP attenuated 
TGF-β1-induced epithelial-mesenchymal transition in A549 cells [113]. Additionally, Ac-SDKP in 
mice exposed to bleomycin, attenuated pulmonary edema, leukocyte infiltration and expression of 
IL-17 and TGF-β, reduced collagen content in the lungs and even improved survival [112]. 
Importantly, it even reversed already established pulmonary fibrosis [112]. Thus, Ac-SDKP may 
play a beneficial role in preventing chronic complications of acute lung injury. 
Due to their anti-inflammatory and antifibrotic properties, certain non-classical RAS molecules 
other than ACE2 might represent a potential therapeutic target as well. However, their role in the 
pathogenesis of acute lung injury and ARDS as well as the possibility of their therapeutic 
modulation have yet to be elucidated. 
9. Perspectives for Drug Development 
Considering the unfavorable prognosis of ARDS and the lack of effective treatment [2,4], there 
is an urgent need for new therapeutic options. RAS modulating therapies might target several 
processes involved in the pathogenesis of ARDS (Table 2), such as excessive inflammation, increased 
vascular permeability as well as fibrotic remodeling of the lungs. In addition, in the context of the 
ongoing pandemic, agent-specific strategies aimed at eliminating the cell entry and/or replication of 
the pathogen are also of considerable importance. 
The experimental administration of Ang 1–7 in several models of acute lung injury showed 
some protective potential. In a two-hit ARDS model (acid- and ventilation-induced injury) in rats, 
the administration of Ang 1–7 improved blood oxygen saturation, reduced the number of 
inflammatory cells in bronchoalveolar lavage fluid and reduced fibrosis in later stages of ARDS [36]. 
Improved oxygenation and alleviated inflammation related to Ang 1–7 treatment were also 
documented in LPS-induced lung injury in mechanically ventilated rats [115]. Moreover, Ang 1–7 
suppressed LPS-induced AT1R mRNA expression in Sprague Dawley rats [30]. 
The administration of recombinant human ACE2 (rhACE2) could be another hopeful strategy 
[34,35,116]. This approach was associated with improved pulmonary function, alleviated 
inflammation as well as attenuated fibrotic remodeling in the lungs in animal experiments [34,35]. In 
the case of SARS-CoV or SARS-CoV-2 infection, increased sACE2 availability could bind and 
inactivate the virus, resulting in the reduced entry of the virus into the cells through the 
membrane-bound ACE2 [115]. The pharmacological properties of rhACE2 have already been 
studied on healthy volunteers as well as ARDS patients and the intravenous administration of the 
molecule was shown to be well tolerated without any relevant cardiovascular side effects [117,118]. 
ACE2 inhibition represents an alternative approach proposed to inhibit the entry of 
SARS-CoV-2 into the target cells [116]. However, this treatment could presumably also suppress 
Ang II conversion to Ang 1–7 by ACE2 and enhance the activity of the pro-inflammatory RAS axis. 
On the other hand, it has been suggested that treatment with a putatively competitive ACE2 agonist 
with higher receptor affinity compared to SARS-CoV or SARS-CoV-2 might block the internalization 
of the virus and stimulate ACE2/Ang 1–7-mediated signaling [25]. In addition, it seems logical to 
suppose that the stimulation of the ACE2/Ang 1–7 axis, e.g., by Ang 1–7, rhACE2 or ACE2 agonists 
in co-treatment with established agents inhibiting ACE or AT1R, could offer additional protection 
compared to monotherapy. 
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Table 2. Effect of angiotensin 1–7 and angiotensin-converting enzyme 2 in animal models of acute 
lung injury (ALI)/acute respiratory distress syndrome (ARDS). 
Treatment Experimental Model Effect of Treatment Ref. 
Ang 1–7 
LD: 0.27 μg/kg/h i.v. 
HD: 60 μg/kg/h i.v.  
Late-ARDS-study: 300 
μg/kg/d i.v. 
Sprague Dawley rats 
HCl- and 
ventilation-induced injury 
Late-ARDS- study: 2 weeks 
post-injury 
Improved oxygenation (PaO2/FiO2) 
↓ WBC in peripheral blood 
Late-ARDS: ↓ hydroxyproline content in 
lung 
HD: ↓ inflammatory cells in BAL  
[36] 
Ang 1–7 
2.4 μg/kg/h i.v.  
Sprague Dawley rats 
LPS- and 
ventilation-induced ARDS 
↑ PaO2 
↑ACE2 and Ang 1–7 in BAL 
Normalized Ang-(1–7)/Ang II ratio$ 
↓ CINC-3, TNF-α, GM-CSF in BAL 
[115] 
Ang-1–7  
600 μg/kg/d i.p. 
Sprague Dawley rats 
LPS-induced early 
pulmonary fibrosis 
↓ lung injury and lung fibrose scores 
↓ TGF-β in plasma 
↓ Ang II in BAL 
Normalized E-cadherin and vimentin 
levels in lung 
↓ AT1R mRNA expression in lung 
↓ cell-membrane AT1R and ↑ MasR in lung 
↓ LPS-induced phosphorylation of Src 
kinase 
[30] 
Ang 1–7 
100 ng/kg/min s.c.  
C57BL/6 mice 
LPS-induced ALI 
↓ edema, bleeding, collagen and septal 
widening in lung 
↓ TGF-β and p-SMAD2/3 in lung 
[119] 
ACE2 
2 mg/kg i.p. 
C57BL6 mice 
BLM-induced ALI 
↑ survival, exercise capacity, lung function 
(dynamic compliance and elastance)  
↓ collagen, α-SMA, TGF-β1, TNF- α in lung 
[34] 
ACE2 
1.0 mg/kg i.v.  
C57BL/6 mice 
LPS-induced ALI 
↓ lung W/D  
↓ PaCO2 and ↑ PaO2 
↓ lung histological score  
↓ IL-1β, IL-6 and TNF-α in lung and in 
serum  
↓ protein concentration and neutrophil 
count in BAL 
↓ LPS-activated TLR4-signaling 
[35] 
ARDS—acute respiratory distress syndrome; ALI—acute lung injury; Ang 1–7—angiotensin 1–7; 
ACE2—angiotensin-converting enzyme 2; Ang II—angiotensin II; AT1R—angiotensin II-receptor 
type 1; i.v.—intravenously; i.p. intraperitoneally; s.c.—subcutaneously; HD—high dose; LD—low 
dose; BAL—bronchoalveolar lavage; HCl—hydrochloric acid; LPS—lipopolysaccharide; 
BLM—bleomycin; PaCO2—partial pressure of carbon dioxide; PaO2—partial pressure of oxygen; 
FiO2 –fraction of inspired oxygen; WBC—white blood cells; TNF-α—tumor necrosis factor α; 
TGF-β—transforming growth factor β; IL—interleukin; α-SMA—alpha smooth muscle actin; 
TLR—toll like receptor; CINC-3—cytokine-induced neutrophil chemoattractant 3; 
GM-CSF—granulocyte-macrophage colony-stimulating factor; W/D—weight/dry weight ratio. 
10. Conclusions 
The role of the RAS is much more complex than vascular tone regulation or cardiac remodeling 
modulation; still, its effects beyond the cardiovascular system are less understood. Recent data 
suggesting that the RAS might be one of the principal regulatory systems controlling the immune 
response in acute lung injury open new horizons for further research in several directions. In the 
course of ARDS, two mechanisms contribute to organ damage: (1) the direct harmful effect of 
etiological factors (e.g., microbial agents, toxins etc.) causing an initial injury, and (2) 
immune-induced damage due to exaggerated inflammatory response. The biological functions of 
RAS-associated molecules, at least in relation to pulmonary tissue damage, should not be viewed as 
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black or white. Their roles change dynamically during the development of acute lung injury to 
ensure, on one hand, an adequate immune defense and, on the other hand, pulmonary tissue 
restoration once the damaging factor has been eliminated. 
The dominance of the classical ACE/AngII/AT1R pathway seems to be desirable in protecting 
the tissue against the initial injury caused by the etiological agent itself. In later phases, increased 
ACE2 activity presumably attenuates the immune response and protects against exaggerated 
inflammation associated with cytokine storm, profound tissue alterations and the fibrotic 
remodeling of the lungs. This increase in ACE2 activity might be decisive for tissue repair. Several 
pathogens have been shown to decrease the expression and/or activity of ACE2, which could lead to 
increased bioavailability of Ang II, DABK or Ang A as well as decreased levels of certain 
counterregulatory molecules, such as Ang 1–7 or alamandine. The disrupted equilibrium within the 
RAS could at least partly explain the mechanisms deteriorating and complicating the course of acute 
lung injury. The pilot experimental data suggest that targeting RAS-associated molecules might 
represent a novel and promising approach in ARDS therapy. However, numerous questions remain 
unresolved and the following research directions should be encouraged: 
— First, the roles of membrane-bound and soluble ACE2 in the respiratory tract as well as the 
biological significance of ACE2-shedding under physiological and pathological conditions 
should be elucidated. 
— The interaction mechanisms of particular infectious agents with the RAS, especially ACE2, are 
of importance for specific therapeutic approaches. 
— Besides ACE2, other non-classical components of the RAS could also play a significant role in 
the pathogenesis of acute lung injury and ARDS. 
— The biological impact of established RAS modulating therapies (ACEIs or ARBs) on RAS 
molecules should be disclosed in ongoing clinical trials. 
A more profound understanding of the RAS role in the pathogenesis of acute lung injury and 
ARDS could shed more light on the therapeutic approach to the acute respiratory distress syndrome. 
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Abbreviations 
α-SMA  α-smooth muscle actin 
ACE  angiotensin converting enzyme 
ACEIs angiotensin converting enzyme inhibitors 
Ac-SDKP N-acetyl-seryl-aspartyl-lysyl-proline 
ADAM17 tumor necrosis factor-α-converting enzyme (TACE) 
ALI acute lung injury 
Ang angiotensin 
APA aminopeptidase A 
APM  aminopeptidase M 
ARBs angiotensin II type 1 receptor blockers 
ARDS acute respiratory distress syndrome  
AT1R angiotensin II type 1 receptor 
AT2R angiotensin II type 2 receptor 
BAL bronchoalveolar lavage 
BLM bleomycin 
CATA cathepsin A 
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CINC-3  cytokine-induced neutrophil chemoattractant 3 
COPD chronic obstructive pulmonary disease 
CxA carboxypeptidase A 
CXCL5 C-X-C motif chemokine 5 
DABK des-Arg9-bradykinin 
DOCA deoxycorticosterone acetate 
FiO2 fraction of inspired oxygen 
GM-CSF  granulocyte-macrophage colony-stimulating factor 
HD high dose 
ICU intensive care unit 
IL interleukin 
i.p. intraperitoneally 
i.v.  intravenously 
KC C-X-C motif chemokine 1 
LD low dose 
LPS lipopolysaccharide 
mACE2 membrane-bound angiotensin converting enzyme 2 
MasR Mas receptor 
MCP-1 monocyte chemoattractant protein-1 
MIP2 macrophage inflammatory protein-2 
MLDAD mononuclear leukocyte-derived aspartate decarboxylase 
MrgD Mas-Related G-Protein Coupled Receptor D 
NEP neprilysin 
PaCO2 partial pressure of carbon dioxide 
PaO2 partial pressure of oxygen 
POP propyl oligopeptidase 
PKC-δ protein kinase C-δ 
RAS renin–angiotensin system 
rhACE2 recombinant human angiotensin converting enzyme 2 
sACE2  soluble angiotensin converting enzyme 2 
s.c. subcutaneously 
T2D type 2 diabetes mellitus 
TACE tumor necrosis factor-α-converting enzyme (ADAM17) 
TGF-β1 transforming growth factor β1 
TLR  toll like receptor 
TMPRSS2  transmembrane protease serine 2  
TNF-α tumor necrosis factor-α 
WBC white blood cells 
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